Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri

Berek, Jonathan S.; Matsuo, Koji; Grubbs, Brendan H.; Gaffney, David K.; Lee, Susanna I.; Kilcoyne, Aoife; Cheon, Gi Jeong; Yoo, Chong Woo; Li, Lu; Shao, Yifeng; Chen, Tianhui; Kim, Miseon; Mikami, Mikio

doi:10.3802/jgo.2019.30.e40

Cited by 38 publications

(28 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…UCSs account for less than 5% of all uterine tumors, however, a recent study conducted in the USA has reported that the rate of this disease has significantly increased over time, possibly due to the increase of number of older patients, obesity, increased use of tamoxifen, etc. (Pothuri et al 2006 ; Onstad et al 2016 ; Matsuo et al 2018 ). Even though UCSs are considered as metaplastic endometrial carcinomas (EC), their aggressiveness is much higher compared to the classical EC; indeed, the proportion of stage I–II is lower in UCSs compared to EC, and, even in early stage, UCSs patients experience worse prognosis with a 5-years survival of 60% (Gonzalez Bosquet et al 2010 ).…”

Section: Introductionmentioning

confidence: 98%

Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study

Corrado

Ciccarone

Cosentino

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

Objective The aim of this retrospective study was to compare surgical and survival outcome in only patients with early-stage UCSs managed by laparotomic surgery (LPT) versus minimally invasive surgery (MIS). Methods Data were retrospectively collected in four Italian different institutions. Inclusion criteria were UCS diagnosis confirmed by the definitive histological examination, and stage I or II according to the FIGO staging system. Results Between August 2000 and March 2019, the data relative to 170 patients bearing UCSs were collected: of these, 95 were defined as early-stage disease (stage I–II) based on the histological report at the primary surgery, and thus were included in this study. Forty-four patients were managed by LPT, and 51 patients were managed by MIS. The operative time was lower in the MIS group versus the LPT group (p value 0.021); the median estimated blood loss was less in the MIS group compared to the median of LPT group (p value < 0.0001). The length of hospital stay days was shorter in the MIS patients (p value < 0.0001). Overall, there were eight (8.4%) post-operative complications; of these, seven were recorded in the LPT group versus one in the MIS group (p value 0.023). There was no difference in the disease-free survival (DFS) and overall survival (OS) between the two groups. Conclusion There was no difference of oncologic outcome between the two approaches, in face of a more favourable peri-operative and post-operative profile in the MIS group.

show abstract

Section: Introductionmentioning

confidence: 98%

Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study

Corrado

Ciccarone

Cosentino

et al. 2020

J Cancer Res Clin Oncol

View full text Add to dashboard Cite

show abstract

“…Stages are further subdivided based on the lesion’s maximum diameter: stage IB3, diameter of ≥4 cm; and stage IIA2, diameter of ≥4 cm. 33 Cervical cancer is diagnosed most frequently in middle-aged women between the ages of 35 and 44 years. It rarely develops in women younger than 20 years.…”

Section: Discussionmentioning

confidence: 99%

A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer

Nguyen

Choi

Kim

et al. 2020

Molecular Therapy - Oncolytics

View full text Add to dashboard Cite

Cervical cancer is the fourth most common cancer in women worldwide. The current approaches still have limitations in predicting the therapy outcome of each individual because of cancer heterogeneity. The goal of this study was to establish a gene expression signature that could help when choosing the right therapeutic method for the treatment of advanced-stage cervical cancer. The 666 patients were collected from four independent datasets. The 70-gene expression signature was established using univariate Cox proportional hazard regression analysis. The 70-gene signature was significantly different between low- and high-risk groups in the training dataset (p = 4.24e−6) and in the combined three validation datasets (p = 4.37e−3). Treatment of advanced-stage cancer patients in the high-risk group with molecular-targeted therapy combined with chemoradiotherapy yielded a better survival rate than with only chemoradiotherapy (p = 0.0746). However, treatment of the patients in the low-risk group with the combined therapy resulted in significantly lower survival (p = 0.00283). Functional classification of 70 genes revealed involvement of the angiogenesis pathway, specifically phosphatidylinositol 3-kinase signaling (p = 0.040), extracellular matrix organization (p = 0.0452), and cell adhesion (p = 0.011). The 70-gene signature could predict the prognosis and indicate an optimal therapeutic modality in molecular-targeted therapy or chemotherapy for advanced-stage cervical cancer.

show abstract

“…Cervical cancer is the fourth most common female malignancy in the world, 1 , 2 accounting for 4% of all tumours diagnosed globally. About 50.3% of patients with cervical cancer die each year from the disease.…”

Section: Introductionmentioning

confidence: 99%

Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D

Wang

Kang

et al. 2020

J Int Med Res

View full text Add to dashboard Cite

Objective To investigate the role of fucoxanthin, reported to have significant anticancer effects, and histone Cluster 1 H3 Family Member D (HIST1H3D; implicated in tumorigenesis) in cervical cancer. Methods The half maximal inhibitory concentration (IC50) of fucoxanthin against HeLa and SiHa cervical cancer cells was determined. Differentially expressed genes (DEGs) in SiHa cells treated with IC50 fucoxanthin were screened by high-throughput techniques and subjected to signal enrichment. Following identification of HIST1H3D as a candidate gene, HIST1H3D-knockdown models were created via transfection with a short hairpin HIST1H3D payload. Impacts on cell proliferation, cell-cycle distribution, colony formation, and apoptosis were studied. Results The fucoxanthin IC50 was 1 445 and 1 641 µM (Hela and SiHa cells, respectively). Chip results revealed 2 255 DEGs, including 943 upregulated and 1 312 downregulated genes, in fucoxanthin-treated versus untreated SiHa cells. Disease and function analysis indicated that these DEGs are primarily associated with cancer and organismal injuries and abnormalities, and online integrated pathway analysis showed that the DEGs were mainly enriched in p53 signalling. HIST1H3D was significantly downregulated in response to fucoxanthin. Inhibition of HIST1H3D mRNA significantly reduced cell proliferation and colony formation, significantly augmented the percentage of apoptotic HeLa and SiHa cells, and cells were arrested in G0/G1 cell cycle phase. Conclusion The results suggest that HIST1H3D may be an oncogene in cervical carcinogenesis and a potential fucoxanthin target in treating cervical cancer.

show abstract

Multidisciplinary perspectives on newly revised 2018 FIGO staging of cancer of the cervix uteri

Cited by 38 publications

References 27 publications

Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study

Role of minimally invasive surgery versus open approach in patients with early-stage uterine carcinosarcomas: a retrospective multicentric study

A 70-Gene Signature for Predicting Treatment Outcome in Advanced-Stage Cervical Cancer

Fucoxanthin may inhibit cervical cancer cell proliferation via downregulation of HIST1H3D

Contact Info

Product

Resources

About